Therapeutic Anti-Tumor Efficacy of DC-Based Vaccines Targeting TME-Associated Antigens Is Improved When Combined with a Chemokine-Modulating Regimen and/or Anti-PD-L1

Autor: Jennifer L. Taylor, Kathleen M. Kokolus, Per H. Basse, Jessica N. Filderman, Chloe E. Cosgrove, Simon C. Watkins, Andrea Gambotto, Devin B. Lowe, Robert P. Edwards, Pawel Kalinski, Walter J. Storkus

Publikováno v: Vaccines, Vol 12, Iss 7, p 777 (2024)

We previously reported that dendritic cell (DC)-based vaccines targeting antigens expressed by tumor-associated vascular endothelial cells (VECs) and pericytes effectively control tumor growth in translational mouse tumor models. In the current repor

Externí odkaz: https://doaj.org/article/d89de03438f041a29bc5602044bdd7d6

Finding the right help in the tumor microenvironment

Autor: Jessica N. Filderman, Walter J. Storkus

Publikováno v: The Journal of Clinical Investigation, Vol 132, Iss 12 (2022)

Tumor-infiltrating lymphocytes (TILs) contain substantial numbers of CD4+ T cells mediating pro- and antitumor functions. While CD4+ Tregs are well characterized and known to promote tumor immune evasion, the fingerprint of CD4+ Th cells that recogni

Externí odkaz: https://doaj.org/article/38db6302f5984895a63c6feccf8dcc1a

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Autor: Jennifer L. Taylor, Hussein Abdul-Hassan Tawbi, Lauren Miller, Jessica N. Filderman, Timothy J. Looney, Manoj Chelvanambi, John M. Kirkwood, Yan Lin, Deena M. Maurer, Melissa DeMark, Lilit Karapetyan, Ronald J Fecek, Walter J. Storkus, Anamika Bose, Lisa H. Butterfield, Geoffrey Lowman, Elizabeth Linch, Ahmad A. Tarhini, Devin B. Lowe, Fei Ding, Amy Rose, Pawel Kalinski

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for immunotherapy of cancer, vol 9, iss 11

BackgroundA first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2+

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f64e2b33170ed2494c9b7122765e2cf
https://pubmed.ncbi.nlm.nih.gov/34782430

584 Therapeutic vascular normalization to promote tumor-associated tertiary lymphoid structures

Autor: Walter J. Storkus, Jessica N. Filderman, Manoj Chelvanambi

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background Tertiary lymphoid structures (TLS) are non-encapsulated immune cell aggregates that form at sites of chronic inflammation, including in and around tumors. Recent studies have shown that the presence of TLS in human tumors is an indicator o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73d4119b147370adb6d24b91cf793758
https://doi.org/10.1136/jitc-2020-sitc2020.0584

762 STING agonism combined with arginase, NOS2, and PTGES/COX2 inhibitors for improved anti-tumor immunotherapeutic benefit

Autor: Walter J. Storkus, Manoj Chelvanambi, Jessica N. Filderman

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundTertiary lymphoid structures (TLS) are non-encapsulated immune cell aggregates that form at sites of chronic inflammation. Recent studies have shown that the presence of TLS in human tumors predicts extended survival and superior response t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed9b3a3fbf1205a6f64326f5b9930b58
https://doi.org/10.1136/jitc-2021-sitc2021.762